COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.

Research Base: Wake Forest University Health Sciences
NCT ID: NCT03475186
NCI Protocol Number: WF-1801
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Condition

Glioblastoma, Radiotherapy; Complications, Cognitive Decline, Chemoradiation

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP